Asset Details
Do you wish to reserve the book?
BRCAness revisited
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
BRCAness revisited
Do you wish to request the book?
BRCAness revisited
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
BRCAness revisited
2016
Overview
The development of therapeutic approaches that target BRCA-mutant tumours has led to the possibility of expanding the range of patients who may benefit from such strategies. Tumours with 'BRCAness', a similar phenotype to germline BRCA-mutant tumours, are increasingly being identified, and this Opinion article discusses the advances and challenges in this context.
Over the past 20 years, there has been considerable progress in our understanding of the biological functions of the
BRCA1
and
BRCA2
cancer susceptibility genes. This has led to the development of new therapeutic approaches that target tumours with loss-of-function mutations in either
BRCA1
or
BRCA2
. Tumours that share molecular features of BRCA-mutant tumours — that is, those with 'BRCAness' — may also respond to similar therapeutic approaches. Several paradigm shifts require a reassessment of the concept of BRCAness, how this property is assayed and its relevance to our understanding of tumour biology and the treatment of cancer.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Antineoplastic Agents - pharmacology
/ Biomarkers, Tumor - analysis
/ Biomarkers, Tumor - genetics
/ Cancer
/ Defects
/ DNA
/ Drug Resistance, Neoplasm - drug effects
/ Drug Resistance, Neoplasm - genetics
/ Female
/ Genetic Predisposition to Disease
/ Genomes
/ Genomics
/ Humans
/ Mutation
/ Poly(ADP-ribose) Polymerase Inhibitors - pharmacology
/ Proteins
/ Rad51 Recombinase - genetics
/ Rad51 Recombinase - metabolism
/ Tumors
